SecurityFRBA / First Bank (Williamstown NJ) (31931U102)
Institutional Owners46
Institutional Shares7,366,043
Institutional Value$ 103,976,000 USD

Institutional Stock Ownership and Shareholders()

First Bank (Williamstown NJ) (NASDAQ:FRBA) has 46 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 7,366,043 shares. Largest shareholders include FJ Capital Management LLC, Banc Funds Co Llc, Wellington Management Group LLP, Stieven Capital Advisors, L.P., Emerald Mutual Fund Advisers Trust, Vanguard Group Inc, Punch & Associates Investment Management, Inc., Millennium Management Llc, Price Michael F, and Renaissance Technologies LLC.
First Bank (Williamstown NJ) (NASDAQ:FRBA) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-15 13F-HR STATE STREET CORP 51,194 58,604 14.47 709 845 19.18
2018-04-20 13F-HR FIRST MANHATTAN CO 31,703 18,850 -40.54 439 271 -38.27
2018-04-27 13F-HR FIRST NATIONAL BANK & TRUST CO OF NEWTOWN 37,877 37,877 0.00 525 545 3.81
2018-05-14 13F-HR MORGAN STANLEY 7,041 5,447 -22.64 97 78 -19.59
2018-05-11 13F-HR GENDELL JEFFREY L 101,670 89,716 -11.76 1,408 1,292 -8.24
2018-05-14 13F-HR Renaissance Technologies LLC 146,600 144,900 -1.16 2,030 2,087 2.81
2017-02-10 13F-HR BlackRock Investment Management, LLC 1,261 1,261 0.00 11 15 36.36
2018-05-14 13F-HR PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC. 349,860 349,860 0.00 4,846 5,038 3.96
2018-05-15 13F-HR Bank of New York Mellon Corp 12,639 13,169 4.19 175 189 8.00
2018-04-23 13F-HR FIRST TRUST ADVISORS LP 11,415 12,249 7.31 158 176 11.39
2018-05-15 13F-HR Tower Research Capital LLC (TRC) 1,168 927 -20.63 16 13 -18.75
2018-04-18 13F-HR GIRARD PARTNERS LTD. 10,000 0 -100.00 139 0 -100.00
2018-05-15 13F-HR Man Group plc 17,331 250
2018-05-15 13F-HR DEUTSCHE BANK AG\ 51,605 86,032 66.71 714 1,238 73.39
2018-05-15 13F-HR Wellington Management Group LLP 828,341 816,825 -1.39 11,473 11,762 2.52
2018-05-11 13F-HR BANC FUNDS CO LLC 1,244,761 1,273,861 2.34 17,239,940 18,344 -99.89
2018-05-14 13F-HR KENNEDY CAPITAL MANAGEMENT, INC. 112,683 107,637 -4.48 1,561 1,550 -0.70
2018-05-04 13F-HR VICTORY CAPITAL MANAGEMENT INC 34,700 500
2018-05-15 13F-HR BARCLAYS PLC 16,200 10,720 -33.83 224 154 -31.25
2018-04-26 13F-HR EMERALD MUTUAL FUND ADVISERS TRUST 588,963 588,963 0.00 8,157 8,481 3.97
2018-04-26 13F-HR ESSEX INVESTMENT MANAGEMENT CO LLC 132,748 123,698 -6.82 1,839 1,781 -3.15
2018-04-12 13F-HR ACADIAN ASSET MANAGEMENT LLC 0 2,637 0 38
2017-10-26 13F-HR Acrospire Investment Management LLC 3,208 0 -100.00 37 0 -100.00
2018-05-15 13F-HR UBS Group AG 18,313 17,902 -2.24 254 258 1.57
2018-04-19 13F-HR Janney Montgomery Scott LLC 12,000 10,000 -16.67 166 144 -13.25
2018-05-14 13F-HR PRICE MICHAEL F 200,100 200,100 0.00 2,771 2,881 3.97
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 56,234 56,234 0.00 778 809 3.98
2018-05-17 13F-HR Nvwm, Llc 400 400 0.00 6 6 0.00
2018-05-11 13F-HR Tibra Equities Europe Ltd 34,201 492
2017-02-10 13F-HR BlackRock Fund Advisors 1,667 2,207 32.39 14 26 85.71
2018-05-15 13F-HR CREDIT SUISSE AG/ 17,331 250
2018-05-15 13F-HR VANGUARD GROUP INC 536,293 585,946 9.26 7,427 8,437 13.60
2018-05-15 13F-HR GOLDMAN SACHS GROUP INC 12,800 54,271 323.99 177 781 341.24
2018-05-11 13F-HR MACQUARIE GROUP LTD 18,555 15,973 -13.92 257 230 -10.51
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 36,618 26,856 -26.66 438 387 -11.64
2018-05-14 13F-HR RAYMOND JAMES & ASSOCIATES 18,540 18,540 0.00 257 267 3.89
2018-05-15 13F-HR BlueCrest Capital Management Ltd 24,071 347
2018-05-11 13F-HR DIMENSIONAL FUND ADVISORS LP 82,235 121,810 48.12 1,139 1,754 53.99
2018-05-10 13F-HR GREAT WEST LIFE ASSURANCE CO /CAN/ 25 0
2018-05-15 13F-HR BRIDGEWAY CAPITAL MANAGEMENT INC 19,345 55,463 186.70 268 799 198.13
2018-05-15 13F-HR MILLENNIUM MANAGEMENT LLC 90,836 211,822 133.19 1,258 3,050 142.45
2018-04-18 13F-HR/A FNY Partners Fund LP 0 2,842 0 40
2018-05-14 13F-HR FJ Capital Management LLC 1,422,900 1,422,900 0.00 19,706 18,409 -6.58
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 11,769 11,389 -3.23 163 164 0.61
2018-05-11 13F-HR Stieven Capital Advisors, L.P. 597,122 592,722 -0.74 8,270 8,535 3.20
2018-05-09 13F-HR HAVERFORD TRUST CO 37,240 0 -100.00 516 0 -100.00
2018-05-09 13F-HR NORTHERN TRUST CORP 26,456 24,872 -5.99 366 358 -2.19
2018-05-09 13F-HR BlackRock Inc. 43,820 45,794 4.50 607 659 8.57
2018-05-09 13F-HR Private Advisor Group, LLC 20,856 0 -100.00 297 0 -100.00
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 15,844 17,108 7.98 219 246 12.33

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

9h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

9h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Related News Stories

Seacoast Banking Corporation of Florida (SBCF) CEO Dennis Hudson on Acquisition of First Green Bancorp, Inc. (Transcript)

2018-06-12 seekingalpha
Seacoast Banking Corporation of Florida (NASDAQ:SBCF) Acquisition of First Green Bancorp, Inc. Conference Call June 12, 2018 11:00 AM ET (2-0)

UOB ceasing foreign currency banknotes import in Taiwan - sources

2018-05-18 reuters
TAIPEI, May 18 (Reuters) - United Overseas Bank (UOB) will stop supplying foreign currency banknotes to lenders in Taiwan from June 18 amid concern on tighter anti-money laundering rules in the region, four sources with direct knowledge of the matter said. (5-0)

Fed Flags Gradual Rate Hikes: Top 5 Winners

2018-05-03 zacks
The Federal Reserve has kept its key interest rate steady this month but has acknowledged that prices of essential commodities are inching up to desired range, paving the way for gradual rate hikes in the coming months. The comeback of inflation, by the way, is very evident, with business houses paying more for labor, steel, oil and other supplies. (40-0)

CUSIP: 31931U102